Unraveling unclassifiable interstitial lung disease – a multicenter approach

S. Torrisi (Heidelberg, Germany), C. Hyldgaard (Silkeborg, Denmark), S. Kronborg-White (Aarhus, Denmark), C. Ganter (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), E. Bendstrup (Aarhus, Denmark)

Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Session: Clinical aspects of idiopathic pulmonary fibrosis
Session type: E-poster session
Number: 758
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Torrisi (Heidelberg, Germany), C. Hyldgaard (Silkeborg, Denmark), S. Kronborg-White (Aarhus, Denmark), C. Ganter (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), E. Bendstrup (Aarhus, Denmark). Unraveling unclassifiable interstitial lung disease – a multicenter approach. 758

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016

A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016

A single-centre retrospective study to phenotype unclassifiable interstitial lung disease
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020


Clinical characteristics of patients with unclassifiable interstitial lung disease
Source: International Congress 2015 – New insights into IIPs
Year: 2015

PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting
Source: International Congress 2014 – ILDs 6
Year: 2014


Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021



PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Multidisciplinary diagnosis of interstitial lung disease: a retrospective analysis
Source: International Congress 2019 – Medical education
Year: 2019

A pragmatic clinical classification for interstitial lung disease
Source: Annual Congress 2012 - Reclassification of idiopathic interstitial pneumonias
Year: 2012


Prognostic significance of pathologically proven chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs): single center retrospective cohort
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease.
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021



Acute fibrinous and organizing pneumonia: A retrospective study
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015


Unclassifiable interstitial lung disease: a distinct entity with heterogeneous progression
Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children
Year: 2018




Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019




Yoga in patients with fibrosing interstitial lung diseases – a feasibility trial
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


Clinical trials in interstitial lung disease
Source: Eur Respir Mon; 2009: 46: 67–84
Year: 2009

Treatment dilemmas in sarcoidosis - a retrospective cohort study
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013

A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014

A prospective evaluation of lung ultrasonography in patients with fibrotic interstitial lung diseases.
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Analysis of multicentric Castleman’s disease (MCD) with pulmonary lesions
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013